Role of Colony Stimulating Factor 1 (CSF-1) and Its Receptor CSF1R: Macrophage Repolarization for Glioblastoma Treatment
ACS Pharmacology & Translational Science · 2025-10-10 · 8 (10) · 3391-3410
DOI: 10.1021/acsptsci.5c00007 ↗At a glance
Übersichtsarbeit in ACS Pharmacology & Translational Science, published online on 2025-09-12. Written by Gaurisha Alias Resha Ramnath Naik and 8 co-authors. Institution: Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal, Udupi, Karnataka State …. Cited 14 times so far (Crossref); 147 references. The full text is freely available (open access, CC BY 4.0). Funded by: Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal Academy of Higher Education, Science and Engineering Research Board.
Abstract (original language)
Glioblastoma multiforme (GBM) is the most aggressive and prevailing form of primary brain tumor, illustrated by its rapid growth and invasive nature. GBM continues to be highly incurable despite advancements in treatment due to its complex tumor microenvironment (TME) and the unique characteristics of tumor-associated macrophages (TAMs). This review explores the function of macrophages within the TME of GBM, specifically emphasizing the impact of colony-stimulating Factor-1 (CSF-1) and its receptor CSF1R in macrophage biology. The progression, survival, and differentiation of TAMs, which often rely on immunosuppressive properties that contribute to tumor growth and treatment resistance, are facilitated by elevated CSF-1 levels in GBM. The inhibition of CSF1R presents a promising therapeutic strategy, as it selectively targets tumor-promoting macrophages while sparing antitumor macrophages. Preclinical evidence demonstrates improved survival outcomes through CSF1R inhibition in mouse models, highlighting its potential for clinical application. Ongoing clinical trials further investigate this approach, aiming to enhance treatment efficacy for patients with GBM. This review concludes by emphasizing the significance of repolarizing macrophages as a novel therapeutic opportunity in GBM management, alongside emerging trends and future research directions that could lead to breakthroughs in treatment strategies.
Subjects
Author keywords
Authors and institutions
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal, Udupi, Karnataka State 576104, India.
- Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401 Punjab, India.
- Faculty of Pharmacy, Silpokorn University, Nakhorn Pathom 73000, Thailand.
ORCID profiles: Deepanjan Datta, Srinivas Mutalik, Namdev Dhas
Funding
- Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education
- Manipal Academy of Higher Education
- Science and Engineering Research Board
Cite
APA
Naik, G. A. R. R., S P, R., Jadhav, S. R., Pokale, R., Hedayat, P., Datta, D., Prajapati, B., Mutalik, S., & Dhas, N. (2025). Role of Colony Stimulating Factor 1 (CSF-1) and Its Receptor CSF1R: Macrophage Repolarization for Glioblastoma Treatment. ACS Pharmacology & Translational Science, 8(10), 3391-3410. https://doi.org/10.1021/acsptsci.5c00007
Vancouver
Naik GARR, S P R, Jadhav SR, Pokale R, Hedayat P, Datta D, et al. Role of Colony Stimulating Factor 1 (CSF-1) and Its Receptor CSF1R: Macrophage Repolarization for Glioblastoma Treatment. ACS Pharmacology & Translational Science. 2025;8(10):3391-3410. doi:10.1021/acsptsci.5c00007
BibTeX
@article{Naik2025,
author = {Naik, Gaurisha Alias Resha Ramnath and S P, Rachana and Jadhav, Sandesh Ramchandra and Pokale, Rahul and Hedayat, Paniz and Datta, Deepanjan and Prajapati, Bhupendra and Mutalik, Srinivas and Dhas, Namdev},
title = {Role of Colony Stimulating Factor 1 (CSF-1) and Its Receptor CSF1R: Macrophage Repolarization for Glioblastoma Treatment},
journal = {ACS Pharmacology & Translational Science},
year = {2025},
volume = {8},
number = {10},
pages = {3391--3410},
doi = {10.1021/acsptsci.5c00007}
}
EUVIMED